Strategic Analysis of the European Specialty Pharma Market

Frost & Sullivan, March 2009, Pages: 58

This Frost & Sullivan research service titled Strategic Analysis of the European Specialty Pharma Market provides the market overview, market engineering research, competitor analysis and therapeutic area-wise opportunity analysis. This research service includes an examination of how the healthcare delivery models differ from one country to another, the regulatory framework for healthcare companies as well as the regulatory barriers to entry, and the best route to market for both global companies and smaller market participants alike. The following market segments have been covered in this research: cardiovascular diseases, central nervous system disorders, ophthalmology, women’s health, and urology.

This research service provides a strategic analysis of the European specialty pharma market and includes an introduction, market overview, market engineering research, competitor analysis, global therapeutic-area wise opportunity analysis, and strategic recommendations.

Market Overview

Innovative Business Models and Focus on Niche Therapeutic Areas Bolster the European Specialty Pharmaceutical Markets

Confronted by a vast array of challenges such as declining R&D productivity and the loss of patent protection of key brands, participants in the pharmaceuticals market are exploring innovative and novel approaches to developing drugs. Given the high degree of unmet needs in specialised therapeutic areas, focussing on developing drugs for niche areas presents several opportunities for specialty pharma companies. "The competitive pressures in the pharmaceutical industry are driving market participants to create new business models," says the analyst of this research. "For instance, companies focused on pure drug delivery have started to invest in R&D to develop indigenous products, while companies dependent on the in-licensing model are attempting to boost internal pipelines."

Lifecycle management technologies, which were once restricted to drug delivery companies, have gradually been adapted by several specialty pharma and generic companies. However, the commoditisation of several drug delivery technologies is adversely affecting specialty pharmaceuticals. "The increasing uptake of generics in most European countries has undermined the attractiveness of life cycle management of legacy products, especially in the case of sophisticated oral drug-delivery technologies," explains the analyst. "Such increased commoditisation is likely to affect the revenues of companies that are specifically focused on reformulation, with the possibility of bigger companies wanting to acquire them as a part of their expansion plans."

Technological innovation and leadership are expected to be a key differentiating factor in the future. The commoditisation of several drug-delivery technologies, particularly in the oral dosage form arena, is driving companies to invest more in R&D. Additionally, applying technological differentiation strategies to compounds that are available in generic forms provides specialty pharmaceutical firms access to the market segments of mainstream indications without having to invest in expensive brand-building and post-market clinical development strategies. "In a changing competitive environment, only those companies that have demonstrated their ability to innovate, create, and market new products are likely to prosper," concludes the analyst.

Market Sectors

Expert Frost & Sullivan analysts thoroughly examine the following market sectors in this research:

By Application:

- Cardiovascular diseases
- Central nervous system disorders
- Ophthalmology
- Women’s health
- Urology

1 EXECUTIVE SUMMARY

2 GLOSSARY OF TERMS AND RESEARCH METHODOLOGY

- Glossary of Terms
- - List of Terms

- Research Methodology
- - Methodology

3 THE SPECIALTY PHARMACEUTICALS MARKET

- Introduction
- - Definitions
- - Existing and Emerging Business Models
- - Market Overview

- Market Engineering Research
- - Industry Challenges
- - Market Drivers
- - Market Restraints
- - Competitive Structure

4 COMPETITOR ANALYSIS

- Key Competitors
- - Market Share Analysis

5 GLOBAL THERAPEUTIC AREA-WISE OPPORTUNITY ANALYSIS

- Analysis by Segment
- - Cardiovascular Diseases
- - Central Nervous System Disorders
- - Ophthalmology
- - Women's Health
- - Urology
- - Dermatology

6 STRATEGIC RECOMMENDATIONS

- Recommendations
- - Strategies for Specialty Pharma Companies

7 DATABASE OF KEY INDUSTRY PARTICIPANTS

- DKIP
- - Key Market Participants

8 DECISION SUPPORT DATABASES

- DSDs
- - Prevalence of Parkinson's Disease
- - Prevalence of Glaucoma
- - Prevalence of Urinary Incontinence
- - Prevalence of Hypertension
- - Prevalence of Alzheimer's Disease

- List of Figures
- - Specialty Pharma Market: Impact of Top Two Industry Challenges (Europe), 2009-2015
- - Specialty Pharma Market: Market Drivers Ranked in Order of Impact (Europe), 2009-2015
- - Specialty Pharma Market: Market Restraints Ranked in Order of Impact (Europe), 2009-2015
- - Specialty Pharma Market: Competitive Structure (Europe), 2008
- - Decision Support Database: Prevalence of Parkinson's Disease in '000 (World), 1999-2006
- - Decision Support Database: Prevalence of Glaucoma in '000 (World), 1999-2006
- - Decision Support Database: Prevalence of Urinary Incontinence in Million (World), 1999-2006
- - Decision Support Database: Prevalence of Hypertension in Million (World), 1999-2006
- - Decision Support Database: Prevalence of Alzheimer's disease in '000 (World), 1999-2006

Product Samples

A sample for this product is available. Please Login/Register to download this sample.

Customers who bought this item also bought

• The Specialty Pharma Market Outlook: Key Players, New Company Growth Models and Emerging Opportunities
• The 2012 Healthcare Business Market Research Handbook
• The Incidence and Prevalence Database: Global Incidence, Prevalence, Morbidity, Comorbidity, Cost Data, Symptoms and Many Other Health Issues for over 4,500 Diseases and Procedures
• U.S. Injectable Drug Pipeline
• Nitric Oxide - Therapeutics, Markets and Companies
• RNAi - Technologies, Markets and Companies
• PAREXEL Biopharmaceutical R&D Statistical Sourcebook 2012/2013
• Nanobiotechnology Applications, Markets and Companies
• Medical Device Market Opportunities In France, 2012
• U.S. Biotechnology - Therapeutic Monoclonal Antibodies Market